Howard L. Kaufman

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

Robert H.I. Andtbacka, Howard L. Kaufman, Frances A. Collichio et al. · Journal of Clinical Oncology · 2015 · 2.5K citations · Full text

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma

Robert H.I. Andtbacka, Frances A. Collichio, Kevin J. Harrington et al. · Journal for ImmunoTherapy of Cancer · 2019 · 413 citations · Full text

Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial

Kevin J. Harrington, Robert H.I. Andtbacka, Frances A. Collichio et al. · OncoTargets and Therapy · 2016 · 99 citations · Full text

Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study

Howard L. Kaufman, Thomas Amatruda, Tony Reid et al. · Journal for ImmunoTherapy of Cancer · 2016 · 96 citations · Full text

Uterine rupture with the use of PGE2 vaginal inserts for labor induction in women with previous cesarean sections.

Donald R. Taylor, Andrea Doughty, Howard L. Kaufman et al. · PubMed · 2002 · 37 citations